7 results on '"Y. Al Qubati"'
Search Results
2. Onchocerciasis (river blindness): larva-induced eczema (onchodermatitis) from an important oculocutaneous tropical disease spilling over into North America and Europe.
- Author
-
Schwartz RA, Al-Qubati Y, Zieleniewski Ł, Shah R, and Kapila R
- Subjects
- Animals, Europe, Ivermectin therapeutic use, Larva, North America, Eczema, Onchocerciasis complications, Onchocerciasis diagnosis, Onchocerciasis drug therapy, Onchocerciasis, Ocular diagnosis, Onchocerciasis, Ocular drug therapy, Onchocerciasis, Ocular epidemiology
- Abstract
Onchocerciasis is a leading cause of blindness in the world. It may be seen in temperate climates of the United States and Europe in immigrants and travelers from endemic regions, often linked to poverty and war. One should be aware of an incubation period that can be up to 15 months. In its early stage and throughout its course, onchocerciasis has noteworthy skin findings, facilitating diagnosis, as onchodermatitis resembles common eczema with variable degrees of papular, lichenoid, atrophic, and pigmentary alterations, features not suggestive if one is unaware of an individual's immigration and travel history. The same concept applies for the encysted worms (onchocercomas), as they tend to appear as common skin cysts and benign neoplasms. New methods can be employed to increase diagnostic sensitivity and specificity. Ivermectin is the gold standard of therapy, the use of which has almost miraculously eliminated this disease from large areas of the earth. However, its effect remains isolated to microfilariae and can be devastating in those coinfected with Loa loa. Recently, the symbiotic relationship between adult worms and Wolbachia bacteria has been discovered and, with it, the possibility of adding doxycycline as a treatment option. We also discuss coinfection with HIV and other diseases., (© 2019 The International Society of Dermatology.)
- Published
- 2020
- Full Text
- View/download PDF
3. A Serological Survey of Human Onchocerciasis in Yemen.
- Author
-
Mackenzie CD, Al-Kubati AS, Al-Qubati Y, Behan-Braman A, Kubofcik J, Hopkins A, and Nutman TB
- Subjects
- Adolescent, Adult, Animals, Child, Enzyme-Linked Immunosorbent Assay, Epidemiological Monitoring, Female, Humans, Immunoprecipitation, Male, Middle Aged, Onchocerca volvulus isolation & purification, Onchocerciasis blood, Onchocerciasis immunology, Onchocerciasis parasitology, Prevalence, Surveys and Questionnaires, Yemen epidemiology, Antibodies, Helminth blood, Antigens, Helminth blood, Onchocerca volvulus immunology, Onchocerciasis epidemiology
- Abstract
Yemen is a country that has been treating severe cases of oncho-dermatitis since 1992 and is now moving to a program aimed at the elimination of the transmission of Onchocerca volvulus . It is important to ensure that the currently acceptable tools used in epidemiological assessment of onchocerciasis in Africa and Latin America also apply to Yemen. Five hundred and ten blood samples from three known O. volvulus -endemic areas, locations that have never been under a mass treatment program, were tested for the presence of antibodies against a panel of O. volvulus -specific antigens using enzyme-linked immunosorbent assay (Ov16) and luciferase immunoprecipitation system (Ov-FAR-1 and Ov-MSA-1) assays. Overall, 31.4% of the samples tested were positive, with positivity increasing with age. Positivity was seen in 76.5% of those presenting with clinical onchocerciasis but importantly also in more than 28.5% of those defined as free of oncho-dermatitis; these latter individuals are likely to be serving as a source for persistent reinfection. This study supports the use of the current O. volvulus -specific serologic methodology in Yemen.
- Published
- 2018
- Full Text
- View/download PDF
4. Onchocerciasis in Yemen: moving forward towards an elimination program.
- Author
-
Al-Kubati AS, Mackenzie CD, Boakye D, Al-Qubati Y, Al-Samie AR, Awad IE, Thylefors B, and Hopkins A
- Subjects
- Adult, Antiparasitic Agents supply & distribution, Antiparasitic Agents therapeutic use, Humans, Ivermectin supply & distribution, Ivermectin therapeutic use, Onchocerciasis drug therapy, Yemen epidemiology, Disease Eradication organization & administration, Onchocerciasis prevention & control
- Abstract
The onchocerciasis focus in Yemen has been known for many years as an endemic area with unique characteristics, notably the atypical and most severe form of onchodermatitis, known as sowda or reactive onchodermatitis (ROD). The national effort to control the disease began in 1992 as an individual case treatment program by administering ivermectin to those presenting with ROD. The challenging geography of the endemic area and the current political and military unrest both underscore a need for special approaches when attempting to eliminate onchocerciasis from this country. An assessment of the national situation regarding this disease was carried out in 2011-2013 aimed at defining the best approach for moving from individual clinical case treatment to elimination of transmission. The history of the control efforts and the current status of the disease are reviewed and the essential changes needed to a mass drug administration (MDA) approach are identified as the national program addresses elimination. Yemen, despite the current troubles, has shown that it can successfully implement MDA programs despite many difficulties and therefore should be supported in its efforts towards countrywide elimination of this infection; however, success will need renewed national and international efforts.
- Published
- 2018
- Full Text
- View/download PDF
5. Phylogenomics and antimicrobial resistance of the leprosy bacillus Mycobacterium leprae.
- Author
-
Benjak A, Avanzi C, Singh P, Loiseau C, Girma S, Busso P, Fontes ANB, Miyamoto Y, Namisato M, Bobosha K, Salgado CG, da Silva MB, Bouth RC, Frade MAC, Filho FB, Barreto JG, Nery JAC, Bührer-Sékula S, Lupien A, Al-Samie AR, Al-Qubati Y, Alkubati AS, Bretzel G, Vera-Cabrera L, Sakho F, Johnson CR, Kodio M, Fomba A, Sow SO, Gado M, Konaté O, Stefani MMA, Penna GO, Suffys PN, Sarno EN, Moraes MO, Rosa PS, Baptista IMFD, Spencer JS, Aseffa A, Matsuoka M, Kai M, and Cole ST
- Subjects
- Codon, Nonsense, DNA, Bacterial chemistry, Genome, Bacterial, Humans, Microbial Sensitivity Tests, Mycobacterium leprae genetics, Mycobacterium leprae isolation & purification, Anti-Infective Agents pharmacology, Drug Resistance, Bacterial genetics, Mycobacterium leprae drug effects, Phylogeny
- Abstract
Leprosy is a chronic human disease caused by the yet-uncultured pathogen Mycobacterium leprae. Although readily curable with multidrug therapy (MDT), over 200,000 new cases are still reported annually. Here, we obtain M. leprae genome sequences from DNA extracted directly from patients' skin biopsies using a customized protocol. Comparative and phylogenetic analysis of 154 genomes from 25 countries provides insight into evolution and antimicrobial resistance, uncovering lineages and phylogeographic trends, with the most ancestral strains linked to the Far East. In addition to known MDT-resistance mutations, we detect other mutations associated with antibiotic resistance, and retrace a potential stepwise emergence of extensive drug resistance in the pre-MDT era. Some of the previously undescribed mutations occur in genes that are apparently subject to positive selection, and two of these (ribD, fadD9) are restricted to drug-resistant strains. Finally, nonsense mutations in the nth excision repair gene are associated with greater sequence diversity and drug resistance.
- Published
- 2018
- Full Text
- View/download PDF
6. Cutaneous and mucocutaneous leishmaniasis: Differential diagnosis, diagnosis, histopathology, and management.
- Author
-
Handler MZ, Patel PA, Kapila R, Al-Qubati Y, and Schwartz RA
- Subjects
- Amphotericin B administration & dosage, Animals, Antiprotozoal Agents therapeutic use, Biopsy, Needle, Drug Therapy, Combination, Female, Humans, Immunohistochemistry, Incidence, Leishmaniasis, Cutaneous diagnosis, Leishmaniasis, Cutaneous drug therapy, Leishmaniasis, Mucocutaneous drug therapy, Leishmaniasis, Mucocutaneous epidemiology, Leishmaniasis, Mucocutaneous pathology, Male, Prognosis, Risk Assessment, Treatment Outcome, Tropical Climate, Endemic Diseases, Immunocompromised Host, Leishmania isolation & purification, Leishmaniasis, Cutaneous epidemiology, Leishmaniasis, Cutaneous pathology
- Abstract
The diagnosis of leishmaniasis can be challenging because it mimics both infectious and malignant conditions. A misdiagnosis may lead to an unfavorable outcome. Using culture, histologic, and/or polymerase chain reaction study results, a diagnosis of leishmaniasis can be established and treatment initiated. Appropriate management requires an accurate diagnosis, which often includes identification of the specific etiologic species. Different endemic areas have varying sensitivities to the same medication, even within individual species. Species identification may be of practical value, because infections with select species have a substantial risk of visceral involvement. In addition, HIV and otherwise immunocompromised patients with leishmaniasis have a propensity for diffuse cutaneous leishmaniasis. For most New World Leishmania species, parenteral antimonial drugs remain the first line of therapy, while Old World species are easily treated with physical modalities. Historically, live organism vaccination has been used and is effective in preventing leishmaniasis, but results in an inoculation scar and an incubation period that may last for years. A more effective method of vaccination would be welcome., (Copyright © 2014 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
7. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives.
- Author
-
Handler MZ, Patel PA, Kapila R, Al-Qubati Y, and Schwartz RA
- Subjects
- Animals, Antiprotozoal Agents therapeutic use, Disease Progression, Endemic Diseases, Female, Humans, Leishmaniasis, Cutaneous drug therapy, Leishmaniasis, Mucocutaneous diagnosis, Leishmaniasis, Mucocutaneous drug therapy, Leishmaniasis, Mucocutaneous epidemiology, Leishmaniasis, Visceral drug therapy, Male, Prevalence, Prognosis, Risk Assessment, Tropical Climate, Leishmania donovani isolation & purification, Leishmaniasis, Cutaneous diagnosis, Leishmaniasis, Cutaneous epidemiology, Leishmaniasis, Visceral diagnosis, Leishmaniasis, Visceral epidemiology
- Abstract
Leishmaniasis is endemic in 98 countries and territories, with 1.2 million new cases per year, making it a worldwide concern. The deadly visceral form is a leading cause of death from tropical parasitic infections, second only to malaria. Leishmaniasis appears to be increasing in many countries because of extended urbanization. The disease reservoir includes small mammals; parasite transmission occurs via bite of the female phlebotomine sandfly. Disease manifestations vary and largely depend upon the Leishmania species acquired. It may be first evident with a range of findings-from a localized cutaneous ulcer to diffuse painless dermal nodules-or, in the mucocutaneous form, ulceration of the oropharynx. In the potentially deadly visceral form, the internal organs and bone marrow are affected., (Copyright © 2014 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.